Clinical operations
Who Gets Offered Your Trial? Clinical Trial Evidence Brief 02
Review new evidence on trial invitations, recruitment feedback and community engagement, plus NIH’s draft monitoring policy and implications for oncology sponsors.
By Lampgen Clinical Research

5 min read · estimated
What the source reported
Clinical Trial Evidence Brief | Friday, November 13, 2026. Issue 02.
Search window — November 7–13, 2026, expanded to October 15–November 13. Four items qualified, all from the wider window. Two original studies, one systematic review, and one NIH draft policy. No repeats from Issue 01.
Sponsor takeaway — Before increasing recruitment pressure on sites, determine where eligible patients leave the recruitment process and whether the proposed intervention addresses that specific barrier.
1. Recruitment feedback has uncertain benefit
Source — Cerar et al., Clinical Trials · first online October 16, 2026 · wider window · site engagement and performance oversight
What the evidence shows — A systematic review identified four evaluations of audit and feedback, including three randomized evaluations. None of the randomized evaluations demonstrated a statistically significant recruitment benefit. The observational evaluation had critical risk of bias, and heterogeneity prevented meta-analysis.
Evidence strength — Limited for effectiveness. Only one randomized evaluation had low risk of bias. The findings leave uncertainty about which feedback approaches work and under what conditions.
Sponsor-side implication — A recruitment ranking or performance email needs its own evaluation before it becomes the main response to a site shortfall.
Practical takeaway — The study manager should pair one feedback intervention with a documented barrier and review screening activity and enrollment after four weeks.
Oncology relevance — Transferable. Test the approach against a specific constraint such as referral follow-up or coordinator capacity. An oncology-specific benefit was not established.
Primary source — reference 1 below.
2. Eligible patients can be lost before anyone offers participation
Source — Dinnissen et al., Journal of Clinical Psychopharmacology · first online November 6, 2026 · wider window · site engagement and recruitment execution
What the evidence shows — Investigators reviewed recruitment into a four-center pediatric risperidone discontinuation trial. The lead center tracked 1,008 prescreened patients. Among eligible patients, 60.1% received study information and 10.8% consented. Approximately 40% were never invited.
Evidence strength — Moderate for describing this recruitment process. The detailed quantitative analysis came from one center, with reasons categorized retrospectively. The underlying trial ran in 2016–2017.
Sponsor-side implication — The eligible population can exceed the number actually offered participation. Separate those milestones when reviewing feasibility and site performance.
Practical takeaway — The site engagement lead should review eligible-but-not-approached counts and documented reasons at the next recruitment meeting.
Oncology relevance — Transferable. Test whether the invitation occurs before the next treatment decision closes the opportunity. This is an oncology application proposed by Lampgen, drawn from psychiatric research.
Primary source — reference 2 below.
3. Documented community engagement was associated with faster enrollment
Source — Ledford et al., Journal of Clinical and Translational Science · first online November 6, 2026 · wider window · site and community engagement
What the evidence shows — Researchers examined 619 trials associated with southeastern U.S. medical schools. Among 349 trials with publications, eight described community engagement. Those eight had higher enrollment and shorter time to full enrollment. Differences in the proportion of the enrollment target achieved and retention were not statistically significant.
Evidence strength — Limited for estimating benefit. The small exposed group, observational design, and reliance on published descriptions constrain interpretation. Undocumented engagement could have been missed.
Sponsor-side implication — Community engagement merits a measured pilot. This study cannot support a predictable enrollment uplift in a forecast.
Practical takeaway — The feasibility lead should define one community engagement pilot before activation, with an owner, budget, and referral-to-enrollment measures.
Oncology relevance — Transferable. Cancer trials were included in the sampling framework, but the reported associations were pooled across conditions.
Primary source — reference 3 below.
4. NIH proposes broader monitoring based on study risk
Source — NIH, NOT-OD-27-006 · released November 2, 2026 · wider window · risk-based monitoring and quality management · draft policy consultation
What the evidence shows — NIH proposes extending data and safety monitoring expectations to all NIH-supported clinical research, with monitoring plans proportionate to study risk and approved by the relevant NIH institute, center, or office. The proposal would replace blanket DSMB requirements for all phase III or multisite trials with risk-based decisions. Comments close January 6, 2027.
Evidence strength — Limited for operational effectiveness: no comparative effectiveness evidence is provided. This is an authoritative NIH draft policy consultation, not a final requirement.
Sponsor-side implication — Teams collaborating on NIH-supported research can assess potential changes while continuing to meet applicable current requirements.
Practical takeaway — The quality lead should prepare a gap assessment identifying affected studies, monitoring responsibilities, and questions requiring NIH clarification.
Oncology relevance — Transferable. Relevant to NIH-supported oncology collaborations, including specimen and observational research. Applicability depends on the funding and study arrangements.
Primary source — reference 4 below.
Coverage gaps
The search covered risk-based monitoring, site engagement, CRA oversight, and clinical trial quality management. No qualifying new comparative study of CRA oversight models or risk-based monitoring effectiveness was found. No new empirical quality-management report met the selection criteria. Decisions about monitoring frequency and source data verification still require trial-specific assessment.
What this means for trial teams
At the next oncology recruitment review, trace one delayed invitation from verified eligibility to the responsible clinician and coordinator. Record the reason for the delay, the next action, and when the team will check whether the patient received an opportunity to discuss the trial. Review the same pattern across sites before deciding whether the problem needs added capacity, a clearer handoff, or a different referral process. Clinical decisions and protocol requirements remain with the sponsor’s agreed process.
Lampgen’s interpretation uses SIGNAL™ to connect an observation to investigation, a study-wide review, an accountable action, and a check on what changed. An untested workflow proposal should be evaluated against a defined milestone and its documented barriers.
Analysis by Tommy Lampley, Jr., M.S., Founder, Lampgen Clinical Research. Published November 13, 2026.
Sources
- Cerar et al. — Audit and feedback interventions for recruitment and retention in clinical trials
- Dinnissen et al. — Challenges of Recruiting Children and Adolescents Into a Randomized Controlled Risperidone Discontinuation Trial
- Ledford et al. — Connecting community engagement to enrollment and retention in clinical trials
- NIH — Draft Policy Update to the NIH Policy for Data and Safety Monitoring
- Related Lampgen insight — recruitment denominators
- Related Lampgen insight — screen-failure review
- Lampgen SIGNAL™ — illustrative worked case